Johnson & Johnson Newsroom

Johnson & Johnson Is Maintained at Outperform by RBC Capital

Dow Jones02:57 · Ratings

Johnson & Johnson Analyst Ratings

Benzinga02:45 · Ratings

Verb Surgical Granted US Patent # 12,108,928 B2 For MACHINE-LEARNING-BASED VISUAL-HAPTIC SYSTEM FOR ROBOTIC SURGICAL PLATFORMS

BenzingaOct 8 23:05

Johnson & Johnson's (NYSE:JNJ) Has Had A Decent Run On The Stock Market: Are Fundamentals In The Driver's Seat?

Yahoo FinanceOct 8 21:00

RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Raises Target Price to $178

Futu NewsOct 8 20:31 · Ratings

Goldman Sachs Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Raises Target Price to $162

Futu NewsOct 8 20:31 · Ratings

Express News | J&J : RBC Raises Target Price to $178 From $175

BreakingsOct 8 17:51

Johnson & Johnson terminates late-stage study of a bladder cancer drug.

Gelonghui October 8th | Johnson & Johnson stated on Monday that it has terminated late-stage studies of an experimental drug for treating bladder cancer because the drug did not show significant advantages over chemotherapy.

Gelonghui FinanceOct 8 15:21

Johnson & Johnson (JNJ.US) has stopped the Phase II study of bladder cancer therapy TAR-200.

Johnson & Johnson has announced that due to disappointing data, the company has halted the Phase II study of TAR-200, a therapy used to treat Muscle-Invasive Bladder Cancer (MIBC) patients.

Zhitong FinanceOct 8 14:09

J&J Discontinues Phase 2 Study for Bladder Cancer Drug TAR-200

Seeking AlphaOct 8 05:04

JNJ Should Continue Higher at Least to Complete a Pullback

FXStreetOct 8 04:38

Express News | J&J - on Target for U.S. FDA Filing of Tar-200 Monotherapy (Sunrise-1) in Non-Muscle Invasive Bladder Cancer in Early 2025

BreakingsOct 8 04:31

Express News | J&J: Sunrise-2 Was Discontinued for Not Showing Superiority Versus Chemoradiation

BreakingsOct 8 04:31

Express News | Johnson & Johnson Statement on Sunrise-2 Study

BreakingsOct 8 04:30

Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference

BusinesswireOct 5 04:30

Sector Update: Health Care Stocks Steady Late Afternoon

MT NewswiresOct 5 03:59

Johnson & Johnson (NYSE:JNJ) Is a Favorite Amongst Institutional Investors Who Own 72%

Simply Wall StOct 4 22:06

Johnson & Johnson Halts Mid-stage Study for Dengue Antiviral

Seeking AlphaOct 4 21:28

Express News | J&J: No Safety Issues Identified to Date in Phase 2 Field Study(Nct05201794)

BreakingsOct 4 21:03

Express News | J&J - Decision to Discontinue Study Part of a Strategic Reprioritization of Company’s Communicable Diseases R&D Portfolio.

BreakingsOct 4 21:01